Prestige Consumer Healthcare (NYSE:PBH) issued an update on its FY19 earnings guidance on Monday morning. The company provided EPS guidance of $2.75-2.78 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.88. The company issued revenue guidance of $970-975 million, compared to the consensus revenue estimate of $989.03 million.
Shares of NYSE:PBH opened at $31.38 on Monday. Prestige Consumer Healthcare has a twelve month low of $27.84 and a twelve month high of $46.44. The company has a market cap of $1.60 billion, a PE ratio of 12.16, a PEG ratio of 1.53 and a beta of 1.19. The company has a current ratio of 2.15, a quick ratio of 1.38 and a debt-to-equity ratio of 1.59.
Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, November 1st. The company reported $0.65 earnings per share for the quarter, topping the consensus estimate of $0.63 by $0.02. Prestige Consumer Healthcare had a return on equity of 11.82% and a net margin of 33.38%. The company had revenue of $239.36 million during the quarter, compared to the consensus estimate of $236.28 million. During the same quarter in the prior year, the company earned $0.61 EPS. The firm’s quarterly revenue was down 7.2% compared to the same quarter last year. Equities analysts predict that Prestige Consumer Healthcare will post 2.88 EPS for the current fiscal year.
In other Prestige Consumer Healthcare news, EVP Timothy Connors sold 34,000 shares of the business’s stock in a transaction dated Monday, November 19th. The stock was sold at an average price of $38.25, for a total transaction of $1,300,500.00. Following the completion of the sale, the executive vice president now owns 25,775 shares of the company’s stock, valued at $985,893.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.14% of the stock is owned by insiders.
About Prestige Consumer Healthcare
Prestige Consumer Healthcare, Inc engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the following segments: North American Over-the-Counter (OTC) Healthcare, International OTC Healthcare, and Household Cleaning. The North American and International OTC Healthcare segments manages the following brands: BC/Goody’s, Beano, Boudreaux’s Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden’s, Monistat, Nix, Pedia-Lax, and Summer’s Eve.
Featured Article: Differences Between Momentum Investing and Long Term Investing
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.